Press Releases
Flamel Technologies Announces Selection of a Flamel Micropump Formulation to Progress to Phase III Clinical Trials
Lyon, France, July 1, 2004 – Flamel Technologies S.A. ("Flamel") (NASDAQ: FLML) announced today that GlaxoSmithKline has selected a Flamel Micropump® formulation for use in an ongoing development project for a major in-line commercial product that has passed all preliminary check points and will progress to Phase III testing
Gerard Soula, PhD., founder, president and chief executive officer of Flamel, said, "We are very excited to be moving forward on this important project with GSK. We are eager to begin the Phase III clinical trials and continue the strong partnership we have developed to date with GSK. We hope that the results of these trials will further demonstrate the potential of our Micropump® technology."
Flamel's Micropump® technology was licensed to GSK for this project in March, 2003.
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release technology for the oral administration of small molecule drugs. Flamel's Medusa® nano-encapsulation technology is designed to deliver therapeutic proteins. Flamel's expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product now marketed by Corning Inc..
This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2003.